论文部分内容阅读
司帕沙星（ｓｐａｒｆｌｏｘａｃｉｎ）是一广谱长效的新型氟喹诺酮类抗菌药。本试验采取多中心随机对照方法，评价了司帕沙星治疗呼吸系统感染的有效性与安全性，选用环丙沙星为对照。两组共治疗患者１２４例，其中司帕沙星组６５例，环丙沙星组５９例。结果显示：司帕沙星对呼吸系统感染的疗效明显优于环丙沙星，统计学有显著性差异（Ｐ＝ ０．０３３），司帕沙星组与环丙沙星组的有效率分别为９２．３％ 和８３．１％ ；两组清除率分别为９２％ 和７８．３％ ；不良反应发生率分别为７．７％ （５／６５）和１３．６％ （８／５９）。试验表明：司帕沙星是一抗菌谱广、抗菌活性强、临床疗效好、不良反应发生少而轻微、服用方便的抗菌药物，对呼吸系统感染疗效肯定确切。
Sparfloxacin is a new broad-spectrum, long-acting fluoroquinolone antibacterial. In this study, a multicentre randomized controlled trial was conducted to evaluate the efficacy and safety of sparfloxacin in the treatment of respiratory infections. Ciprofloxacin was selected as a control. There were 124 co-treated patients in the two groups, including 65 cases in sparfloxacin group and 59 cases in ciprofloxacin group. The results showed that sparfloxacin was superior to ciprofloxacin in the treatment of respiratory infections, the difference was statistically significant (P = 0.033), sparfloxacin and ciprofloxacin respectively Were 92.3% and 83.1% respectively; the clearance rates of the two groups were 92% and 78.3% respectively; the incidences of adverse reactions were 7.7% (5/65) and 13.6% (8/59) . Experiments show that sparfloxacin antibacterial spectrum is broad, strong antibacterial activity, good clinical efficacy, adverse reactions occur in small and mild, easy to take antibacterial drugs, the efficacy of respiratory infections certainly definite.